Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 29, 529-535, March 1, 1969]
© 1969 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leach, W. B.
Right arrow Articles by Schabel, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leach, W. B.
Right arrow Articles by Schabel, F. M., Jr.

Toxicity Studies in Mice Treated with 1-ß-D-Arabinofuranosyl-cytosine (ara-C)1

William B. Leach, W. Russell Laster, Jr.2, Joseph G. Mayo2, Daniel P. Griswold, Jr.2 and Frank M. Schabel, Jr.2

Department of Pathology, University of Alabama Medical Center, Birmingham, Alabama 35233

Optimum therapeutic dosage schedules of 1-ß-D-arabinofuranosylcytosine (ara-C) administered intraperitoneally in mice (15 mg/kg/dose, every 3 hours for 24 hours) result in karyorrhectic damage to the crypt epithelial cells of the intestinal mucosa. This damage is most severe at 4 hours (earliest observations made) following conclusion of the 24-hour course, after which there is a rapid recovery to completion in 72 hours. The damage is thus transitory and resembles that of hydroxyurea. This cycle of transitory intestinal damage followed by recovery occurs after each therapeutic dosage schedule of ara-C as long as the schedule is not repeated more often than every 4th day.

Progressive damage to the intestinal mucosa accompanied by changes in the hematopoietic tissues occurs only if this optimum therapeutic dose (15 mg/kg/dose, every 3 hours) is continued uninterrupted to the LD100 dose (360 mg/kg in 72 hours) and beyond. Irreversible changes are seen in the intestinal mucosa, and a progressive depopulation of the bone marrow with ultimate aplasia ensues as the LD100 dose is reached and surpassed.

1 The part of the work carried out at Southern Research Institute was supported by the Cancer Chemotherapy National Service Center of the National Cancer Institute, under Contract No. PH43-65-594.

2 Kettering-Mayer Laboratory, affiliated with Sloan-Kettering Institute, Southern Research Institute, Birmingham, Alabama.

Received 7/29/68. Accepted 11/ 1/68.




This article has been cited by other articles:


Home page
ScienceHome page
G. Lux, L. Marton, and S. Baylin
Ornithine decarboxylase is important in intestinal mucosal maturation and recovery from injury in rats
Science, October 10, 1980; 210(4466): 195 - 198.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1969 by the American Association for Cancer Research.